Esteemed professor of medicine and infectious diseases at UCLA’s David Geffen School of Medicine, Dr. Claire Panosian Dunavan, unveiled shocking news on September 27, 2024. For the first time, Marburg virus – a relative of Ebola – was discovered to be affecting healthcare workers in two Rwandan hospitals.
Originating in Kigali, Rwanda, the Marburg virus journey began with the infection of 27 individuals, resulting in nine fatalities by September 30. As of October 7, the Rwandan government reported the virus had infected at least 56 individuals and led to 12 deaths. In an early response to curb the virus’s spread, the CDC implemented an international traveler screening procedure from Rwanda, starting the week of October 14. Concurrently, the Sabin Institute dispatched 700 doses of an experimental Marburg vaccine targeting high-risk medical workers and others across six sites in Rwanda.
First identified in 1967 after killing German and Serbian researchers who had contact with infected African monkeys, the Marburg virus is characterized by its pleomorphic virions, often in resemblance of rods, rings, or numeral six. Historically, cases emanating outside Africa were minimal, with only one case reported in a Russian lab worker and fewer than 10 cases in travelers to Africa or their contacts. However, the African narrative differs significantly, with several outbreaks between 1975 till this day, leading to nearly 600 people being infected.
Noteworthy is the fatality rates that range from 24% to as high as 88% in Angola, Democratic Republic of the Congo (DRC), Ghana, Equatorial Guinea, South Africa, Kenya, Tanzania, and Uganda. To further discuss the recurring surge of Marburg and the pressing need for global cooperation for testing and vaccination, a conversation was conducted with Dr. Daniel Bausch, previous president of the American Society of Tropical Medicine and Hygiene, whose three-decade experience with hemorrhagic fevers is unparalleled. Dr. Bausch expressed a mix of astonishment and familiarity with the presence of Marburg in Rwanda and was particularly concerned with the high infection rate of healthcare workers in Rwanda. Countering his surprise was Rwanda’s vaguely better off healthcare capabilities vis-à-vis the DRC. However, his experience during the worst Ebola outbreak (2013 to 2016), suggested that sometimes, healthcare workers treating their colleagues might undertook unprecedented risks. The conversation further pointed to the strategic and moral obligations of wealthier nations to invest in vaccine trials for Marburg and similar emerging diseases. Even though the trials might not always conclude due to the containment of the virus, the prep work lays the foundation for readiness for recurrent outbreaks. The crucial argument to be made is irrespective of geographical boundaries, a threat to one is a threat to all, therefore, controlling these outbreaks at the source is paramount. Whether Rwanda can contain the viral spread domestically and internationally remains uncertain; however, it highlights the necessity for ongoing preparation and investment in tackling Marburg outbreak effectively.
Tags: Healthcare, Infection Prevention, Marburg Virus, Vaccine Development, global cooperation
Source: https://www.medpagetoday.com/opinion/parasites-and-plagues/112339